Neupro approved in Japan for Parkinson’s disease and Restless Legs Syndrome
The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Neupro® (rotigotine transdermal patch) for the treatment of Parkinson’s disease (PD) and for the symptomatic treatment of moderate-to-severe idiopathic restless legs syndrome (RLS) in adults. In 2002 Otsuka Pharmaceutical acquired the rights for developing and marketing Neupro® in Japan. UCB is responsible for development and marketing in all other regions worldwide.
Rotigotine is a once-daily transdermal patch which provides continuous delivery of the dopamine agonist over 24 hours. The Japanese approval of rotigotine is supported by randomized, controlled clinical studies in Japanese patients which have demonstrated its efficacy and safety in the treatment of PD and RLS. These studies have added to the existing data for rotigotine which has led to previous approvals in other regions such as Europe and the US.
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Intercell announces start of pivotal Phase II/III study in India for vaccine to protect children from Japanese Encephalitis
Quotient Clinical and Bend Research Announce Collaboration To Accelerate Advancement of New Medicines

Taking aim at skin bacteria - Enzyme treatment of skin samples improves microbiome analysis

SeaBeLife awarded over €1.5 million in i-Nov innovation competition - Funding for company’s SeaBeEYE project will be used to develop new therapeutic approach for geographic atrophy – advanced form of dry AMD
Autifony Therapeutics announces initiation of Phase IIa study for first-in-class drug to treat tinnitus
